DOI:
10.1055/s-00000011
DMW - Deutsche Medizinische Wochenschrift
LinksClose Window
References
Haas M, Siveke JT, Schenk M. et al.
Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: A prospective phase II study of the ‘Arbeitsgemeinschaft Internistische Onkologie’.
Eur J Cancer 2018;
94: 95-103
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.